The combination of Dapagliflozin therapy with dietary carbohydrate restriction for 12 months in patients with T2D and class 3 obesity resulted in a significant and substantial reduction of body weight, fat mass and serum leptin, but without any discernible compensatory changes in metabolic rate or appetite. The gene discussed is LEP; the disease is obesity disorder.